Efficacy of immunotherapy in KRAS-mutant non-small-cell lung cancer with comutations

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• KRAS mutations are a primary driver in western non-small-cell lung cancer (NSCLC) lung adenocarcinoma.
• Despite KRAS mutation prevalence, no KRAS-specific therapy was FDA-approved until 2021.
• Standard first-line treatment for NSCLC involves immunotherapy or chemoimmunotherapy, irrespective of KRAS status.

Purpose of the Study:

• To investigate the predictive value of KRAS mutations in NSCLC for immunotherapy outcomes.
• To explore the influence of common co-mutations (TP53, STK11/LKB1, KEAP1) on treatment response.

Main Methods:

• Analysis of clinical data from NSCLC patients treated with immunotherapy.
• Correlation of KRAS mutation status and co-mutation profiles with treatment outcomes.

Main Results:

• Outcomes for KRAS-mutant NSCLC patients receiving immunotherapy are not fully elucidated.
• Emerging evidence suggests TP53 co-mutations may be associated with improved immunotherapy outcomes.
• STK11/LKB1 or KEAP1 co-mutations appear linked to worse outcomes with immunotherapy.

Conclusions:

• KRAS mutation status alone may not be sufficient to predict immunotherapy response in NSCLC.
• Co-occurring mutations significantly modify the prognostic impact of KRAS in NSCLC patients undergoing immunotherapy.
• Further research is needed to clarify the role of these co-mutations in guiding treatment decisions.